3 Drugs Approved, but Only 1 Matters

Regeneron Pharmaceuticals (Nasdaq: REGN  ) has gained Food and Drug Administration approval of its third drug, Zaltrap, which treats metastatic colorectal cancer. Three approvals in four years is no small feat.

And yet, it'll be its middle child that will get all the glory for now.

Arcalyst was approved to treat cryopyrin-associated periodic syndromes, but sales have never amounted to much -- $6 million in the second quarter -- because CAPS is an ultra-orphan disease that few people have. Splitting CAPS patients with Novartis' (NYSE: NVS  ) Ilaris, which was approved a year later, didn't help.

The drug could have gained some traction if it had been approved to prevent gout flares, but the FDA panned that idea last week. Regeneron was light on the details beyond that it was rejected, which we knew was coming. Investors should assume that the expansion plans for Arcalyst are dead until further notice.

Zaltrap will certainly sell better than Arcalyst. Even as a second-line indication there will be patients that fail Roche's Avastin or Eli Lilly (NYSE: LLY  ) and Bristol-Myers Squibb's (NYSE: BMY  ) Erbitux, which are both approved in the first-line setting.

But sales of Zaltrap won't contribute to Regeneron's profits initially because under its partnership agreement with Sanofi (NYSE: SNY  ) , Regeneron is required to repay half of the cost of developing Zaltrap out if its profits from the joint venture. The repayment schedule allows Regeneron to keep any quarterly profits that exceed 5% of the outstanding obligation, but it'll be awhile before its share of the profits reaches that level. Zaltrap failed quite a few clinical trials in other types of tumors, which ratcheted up the expenses to $763 million as of the end of last year.

That leaves Regeneron's macular degeneration drug, Eylea, as the immediate future of the biotech. No pressure, kid.

Interested in new technology? Check out the Fool's new report, "The Next Trillion Dollar Revolution." Claim your free copy by clicking here.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1974095, ~/Articles/ArticleHandler.aspx, 12/21/2014 6:26:40 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement